Leukotrienes in rhinitis

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Howarth, Peter H ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE;

ALLERGIC RHINITIS; MEDIATOR RELEASE; MUCOSA INFLAMMATION; NOSE CONGESTION; NOSE SECRETION; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

EID: 0034063820     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-26     Document Type: Review

References (50)

1. Howarth, P. H. 1989. Allergic rhinitis: a rational choice of treatment. Respir. Med. 83:179-188.
2. Howarth, P. H. 1998. Disease pathogenic mechanisms in allergy: a rational basis for treatment. Br. Med. J. 316:757-761.
3. Baraniuk, J. N. 1991. Neural control of human nasal secretion. Pulm. Pharmacol. 4:20-31.
4. Stjarne, P., L. Lundblad, J M. Lundberg, and A. Angaard. 1989. Capsaicin and nicotine-sensitive afferent neurones and nasal secretion in healthy human volunteers and in patients with vasomotor rhinitis. Br. J. Pharmacol. 96:693-701.
5. Enerback, L., U. Pipkorn, and G. Granerus. 1986. Intraepithelial migration of nasal mucosal mast cells in hay fever. Int. Arch. Allergy Appl. Immunol. 80:44-51.
6. Bentley, A. M., M. R. Jacobson, V. Cumberworth, J. R. Barkan, R. Moqbel, L. Schwartz, A.-M. Irani, A. B. Kays, and S. R. Durham. 1992. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J. Allergy Clin. Immunol. 89:877-883.
7. Montefort, S., I. H. Feather, S. J. Wilson, D. O. Haskard, T. H. Lee, S. T. Holgate, and P. H. Howarth. 1992. The expression of leucocyte-endothelial adhesion molecules is increased in perennial allergic rhinitis. Am. J. Respir. Cell Mol. Biol. 7:393-398.
8. Otsuka, H., J. A. Denburg, J. Dolovich, D. Hitch, P. Lapp, R. S. Rajan, J. Bienenstock, and A. D. Betus. 1985. Heterogeneity of metachromatic cells in human nose: significance of mucosal mast cells. J. Allergy Clin. Immunol. 76:695-702.
9. Okuda, M., H. Ohtsuka, and S. Kawabori. 1985. Studies of nasal surface basophilic cells. Ann. Allergy 54:69-71.
10. Peters, S. P., D. W. MacGlashan, E. S. Schulman, R. P. Schleimer, E. C. Hayes, J. Rokach, N. F. Adkinson, and L. M. Lichtenstein. 1984. Arachidonic acid metabolism in purified human lung mast cells. J. Immunol. 132:1972-1979.
11. MacGlashan, D. W., R. P. Schleimer, S. P. Peters, E. S. Schulman, G. K. Adams, H. H. Newball, and L. M. Lichtenstein. 1982. Generation of leukotrienes by purified human lung mast cells. J. Clin. Invest. 70:747-751.
12. 2 and leukotrienes. J. Immunol. 139:494-500.
13. Levi-Schaffer, F. K., K. Austen, P. M. Gravallee, and R. L. Stevens. 1986. Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc. Natl. Acad. Sci. U.S.A. 83:6485-6488.
14. Tsai, M., L.-S. Shin, G. E. J. Newlands, T. Takeishi, K. E. Langley, K. M. Zseho, H. R. P. Miller, E. M. Geissler, and S. T. Galli. 1991. The rat c-Kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo; analysis by anatomical distribution, histochemistry and protease phenotype. J. Exp. Med. 174: 125-131.
15. 2 from human bronchoalveolar cells. Thorax 40:716.
16. MacGlashan, D. W., R. P. Schleimer, S. P. Peters, E. S. Schulman, G. K. Adams, A. Kagey-Sabotka, H. H. Newball, and L. M. Lichtenstein. 1983. Comparative studies of human basophils and mast cells, Fed. Proc. 42:2504-2509.
17. MacGlashan, D. W., S. P. Peters, J. A. Warner, and L. M. Lichtenstein. 1986. Characteristics of human basophil sulphidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J. Immunol. 136:2231-2239.
18. Weller, P. F., C. W. Lee, D. W. Foster, E. J. Corey, K. F. Austen, and R. A. Lewis. 1983. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc. Natl. Acad. Sci. U.S.A. 80:7626-7630.
19. Turk, J., R. L. Maas, A. R. Brash, L. J. Roberts, and J. A. Oates. 1982. Arachidonic acid 15-lipoxygenase products from human eosinophils. J. Biol. Chem. 257:7068.
20. 4 and 15-lipoxygenase products. Immunology 51:679.
21. Frigas, E., and G. J. Gleich. 1987. The role of eosinophils. In M. H. Lessoff, T. H. Lee, and D. M. Kemeny, editors. Allergy: An International Textbook. John Wiley & Sons, Chichester. 137-155.
22. Kita, H., T. Ohnishi, Y. Okuba, D. Weiler, J. S. Abrams, and G. J. Gleich. 1991. Granulocyte macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J. Exp. Med. 174:745-748.
23. Desreumaux, P., A. Janin, J. F. Colombel, L. Prin, J. Plumas, D. Emilie, G. Torpier, A. Capron, and M. Capron. 1992. Interleukin-5 messenger RNA expression in the intestine mucosa of patients with coeliac disease. J. Exp. Med. 175:293-296.
24. Creticos, P. S., S. P. Peters, N. F. Adkinson, Jr., et al. 1984. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N. Engl. J. Med. 310:1626-1630.
25. Pipkorn, U., D. Proud, L. M. Lichtenstein, et al. 1987. Effect of short term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J. Clin. Invest. 80:957-961.
26. 4 in allergic rhinitis. Allergy 40:1-6.
27. 4 in grass-pollen-induced rhinitis. Am. Rev. Respir. Dis. 136:357-362.
28. Brunnee, T., S. Nigam, G. Kunkel, and C. R. Baumgarten. 1991. Nasal challenge studies with bradykinin: influence upon mediator generation. Clin. Exp. Allergy 21:425-431.
29. Ophir, C., A. Fink, A. Eliraz, E. Tabachnik, and Z. Bentwich. 1988. Allergen-induced leukotriene production by nasal mucosa and peripheral blood leucocytes. Arch. Otolaryngol. Head Neck Surg. 114:522-524.
30. 4 as a mediator of early and late reactions to antigen in humans: the effect of systemic glucocorticoid treatment in vivo. Am. Rev. Respir. Dis. 83:634-642.
31. Ramis, I., J. R. Catafan, J. Serra, O. Bulbena, C. Picardo, and E. Gelpi. 1991. In vivo release of 15-HETE and other arachidonic acid metabolites in nasal secretions during early allergic reactions. Prostaglandins 42:411-120.
32. Naclerio, R. M., D. Proud, A. G. Togias, N. F. Adkinson, D. A. Meyers, A. Kagey-Sabotka, M. Plaut, P. S. Norman, and L. M. Lichtenstein. 1985. Inflammatory mediators in late antigen-induced rhinitis. N. Engl. J. Med. 313:65-70.
33. Bascom, R., M. Wachs, R. M. Naclerio, U. Pipkorn, S. J. Galli, and L. M. Lichtenstein. 1998. Basophil influx occurs after nasal challenge: effects of topical corticosteroid pretreatment. J. Allergy Clin. Immunol. 81: 580-589.
34. Togias, A. G., R. M. Nacclerio, S. P. Peters, et al. 1986. Local generation of sulfidopeptide leukotrienes upon nasal provocation with cold, dry air. Am. Rev. Respir. Dis. 133:1133-1137.
35. Ferreri, N. R., W. C. Howland, D. D. Stevenson, and H. L. Spiegelberg. 1988. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am. Rev. Respir. Dis. 137:847-854.
36. Picardo, C., I. Ramis, J. Rosello, J. Prat, O. Bulbena, V. Plaza, J. M. Montserrat, and E. Gelp. 1992. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am. Rev. Respir. Dis. 145:65-69.
37. Knani, J., A. Campbell, I. Enander, C. G. Peterson, R. B. Michel, and J. Bousquet. 1992. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J. Allergy Clin, Immunol. 90:880-889.
38. 4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J. Allergy Clin, Immunol. 82:414-418.
39. Jung, T. T. K., S. K. Juhn, D. Hwang, et al. 1987. Prostaglandins, leukotrienes and other arachidonic acid metabolites in nasal polyps and nasal mucosa. Laryngoscope 97:184-189.
40. 4 in allergic rhinitis. Ann. Allergy 60:537-540.
41. 4 on nasal mucosal blood flow, nasal airways resistance and nasal secretions in humans. Clin. Allergy 16:289-297.
42. Flowers, B. K., D. Proud, A. Kagey-Sabotka, L. M. Lichtenstein, and R. M. Naclerio. 1990. The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol. Head Neck Surg. 102:219-224.
43. Knapp, U. R. 1990. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N. Engl. J. Med. 327:1745-1748.
44. Howarth, P. H., K. Harrison, and L. Lau. 1995. The influence of 5-lipoxygenase inhibition in allergic rhinitis. Int. Arch. Allergy Appl. Immunol. 107:423-424.
45. Fischer, A. R., M. A. Rosenberg, C. M. Lilly, et al. 1994. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J. Allergy Clin. Immunol. 94:1046-1056.
46. 4-receptor antagonist. Eur. J. Pharmacol. 191: 273-280.
47. 4 receptor antagonist, ICI 204:219, relieves symptoms of acute seasonal allergic rhinitis symptoms. Am. J. Respir. Crit. Care Med. 151:1734-1739.
48. Malmstrom, K., E. Meltzer, B. Prenner, et al. 1998. Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis. J. Allergy Clin. Immunol. 101:597.
49. 1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. Br. J. Clin. Pharmacol. 18:1-8.
50. 1-antihistamines, terfenadine and astemizole for hay fever. Thorax 39:668-672.